

Kaya Limited

October 7, 2022

To,

BSE Limited
Market Operations Department,
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
BSE Scrip Code: 539276

National Stock Exchange of India Limited
'Exchange Plaza', 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra(E), Mumbai 400051
NSE Symbol: KAYA

Sub.: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015.

Dear Sir/ Madam,

We would like to inform you that Kaya Middle East DMCC (“**DMCC**”) the wholly owned subsidiary of the Company, is increasing its stake in IRIS Medical Centre LLC, (subsidiary of DMCC) from existing 85% to now 100%.

Therefore, IRIS Medical Centre LLC will become a wholly owned (100%) subsidiary of DMCC.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFO/CMD/4/2015 dated September 9, 2015 are given in Annexure ‘A’ to this letter.

Thanking you.
For **Kaya Limited,**

Nitika Dalmia
Company Secretary &
Compliance Officer
Encl: A/a

Kaya Limited

Details as per the Securities and Exchange Board of India circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015

Annexure 'A'

Name of the target entity, details in brief such as size, turnover etc	IRIS MEDICAL CENTRE LLC, Size = One Clinic Turnover: FY 22: AED 9.8 lakhs. Incorporated as a private company on 15-May-2014. Engaged in the business of Treatment of Dermatology.
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No. The transaction is related to increase of stake and same is being acquired from existing shareholder.
Industry to which the entity being acquired belongs;	Dermatology/Healthcare.
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	DMCC will become 100% beneficiary in the company post acquisition. The target entity is an existing subsidiary of DMCC with 85% economic and beneficiary interest.
Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
Indicative time period for completion of the acquisition	Six months
Nature of consideration - whether cash consideration or share swap and details of the same	Not applicable
Cost of acquisition or the price at which the shares are acquired	AED 22,500

Kaya Limited

Percentage of shareholding /control acquired and / or number of shares acquired	15%
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>IRIS MEDICAL CENTRE LLC, Size = One Clinic</p> <p>Incorporated as a private company on 15-May-2014. Engaged in the business of Treatment of Dermatology.</p> <p>Turnover: FY 22 : AED 9.8 lakhs FY 21: AED 6.6 lakhs FY 20: AED 9.5 lakhs</p>

For Kaya Limited,

Nitika Dalmia
Company Secretary &
Compliance Officer